Form 4: Lexeo Therapeutics CLO Sells Shares for Tax Obligations

Lexeo Therapeutics' Chief Legal Officer, Jenny Robertson, sold 542 shares of common stock to cover tax obligations related to restricted stock units.

Summary

• Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, Inc. (LXEO), sold 542 shares of common stock.
• The transaction occurred on August 18, 2025, at a price of $4.668 per share.
• The sale was executed to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following this transaction, Ms. Robertson beneficially owns 62,556 shares, which includes 51,092 restricted stock units.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• The transaction is a routine sale to cover tax obligations, indicating a standard compensation event rather than a discretionary sale.

Negatives

• A reduction in direct common stock holdings by a key executive, although for a specific tax purpose.

Risks

• No specific risks beyond the routine nature of the transaction are mentioned in this Form 4 filing.

Future Outlook

Not applicable, as this Form 4 filing details a past transaction and does not provide forward-looking statements or guidance.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide broader industry context or trends.

Comparison to Industry Standards

• Not applicable, as this Form 4 filing details a specific insider transaction and does not provide financial results or operational metrics for industry comparison.

Stakeholder Impact

• Shareholders: Minimal direct impact, as the sale is small relative to total shares outstanding and is for a routine tax purpose.
• Employees: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider sale of a small number of shares to cover tax obligations related to restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamentals or an executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Lexeo Therapeutics, LXEO, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Obligations, Executive Compensation, Jenny Robertson